TNF-α but not IL-1α is correlated with PGE1-dependent protection against acute D-galactosamine-induced liver injury

Canadian Journal of Gastroenterology

Volumn 14, Issue 3, 2000, Pages 175-180

  Muntane J ^a   Montero, J L ^a   Lozano, J M ^a   Miranda Vizuete, A ^a   De La Mata, M ^a   Mino G ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Cytokines; D galactosamine; Hepatotoxicity; Interleukin 1 alpha; Liver injury; Nitric oxide; Prostaglandin E1; Tumour necrosis factor alpha

Indexed keywords

ALANINE AMINOTRANSFERASE; GALACTOSAMINE; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; NITRIC OXIDE; PROSTAGLANDIN E1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; INFLAMMATORY CELL; LIVER INJURY; LIVER PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0034030613     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2000/416705     Document Type: Article

References (44)

1. 2 on brain edema and liver histopathology in a galactosamine-induced fulminant hepatic failure rat model. Biomater Artif Cells Artif Organs 1987;15:559-73.
2. Bergasa NV, Borque MJ, Wahl LM, Rabin L, Jones EA. Modulation of thioacetamide-induced hepatocellular necrosis by prostaglandins is associated with novel histologic changes. Liver 1992;12:168-74.
3. 1-induced injury in the rat. Prostaglandins 1989;37:683-93.
4. Stachura J, Tarnawski A, Ivey KJ, et al. Prostaglandin protection of carbon tetrachloride-induced liver cell necrosis in the rat. Gastroenterology 1981;81:211-7.
5. 1 administration in cirrhotic rats. Gastroenterology 1993;105:1483-9.
6. 2 delays collagen formation in nutritional injury in rat liver. Hepatology 1988;8:61-4.
7. 2 prevents the development of fulminant hepatitis and blocks the induction of monocyte/macrophage procoagulant activity after murine hepatitis virus strain 3 infection. J Clin Invest 1987;80:881-9.
8. 2 and dibutyryl cyclic AMP against complement-mediated hepatic necrosis in rats. Hepatology 1991;14:545-50.
9. Sinclair SB, Greig PD, Blendis LM, et al. Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E. J Clin Invest 1989;84:1063-9.
10. Sinclair SN, Levy GA. Treatment of fulminant viral hepatic failure with prostaglandin E. A preliminary report. Dig Dis Sci 1991;36:791-800.
11. 2) and a prostaglandin analogue BW 245C on galactosamine-induced hepatic necrosis. J Hepatol 1986;2:53-64.
12. Limm SP, Andrews FJ, Christophi C, O'Brien PE. Microvascular changes in liver after ischemia-reperfusion injury. Dig Dis Sci 1994;39:1683-90.
13. 2: favorable effects on rat injury. Gastroenterology 1992;102:572-6.
14. 4 in isolated rat hepatocytes. Prostaglandins 1989;37:23-31.
15. 2 inhibits tumor necrosis factor production by Kupffer cells and prevents endotoxin induced mortality in mice. Gastroenterology 1992;102:A846. (Abst)
16. Libert C, Van Bladel S, Brouckaert P, Shaw A, Fiers W. Involvement of the liver, but not of IL-6, in IL-1-induced desensitization to the lethal effects of tumor necrosis factor. J Immunol 1991;146:2625-32.
17. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-42.
18. National Academy of Sciences. Guide for the Care and Use of Laboratory Animals. NIH Publication no 80-83, revised. Bethesda: National Institutes of Health, 1985.
19. Reithman S, Frankel D. A colorimetric method for the determination of serum glutamic oxaloacetic and glutamic pyruvate transaminase. Am J Clin Pathol 1957;28:56-63.
20. 1 on TNF-α status and hepatic D-galactosamine-induced apoptosis in rats. J Gastroenterol Hepatol 1998;13:91-101.
21. Decker K, Keppler D. Galactosamine-induced liver injury. In: Popper H, Schaffner F, eds. Progress in Liver Disease, vol 4. New York: Grune and Stratton, 1972:183-96.
22. El-Mofty S, Scrutton MC, Serroni A, Nicolini C, Farber JL. Early, reversible plasma membrane injury in galactosamine-induced liver cell death. Am J Pathol 1975;79:579-96.
23. Keppler D, Lesch R, Reutter W, Decker K. Experimental hepatitis induced by D-galactosamine. Exp Mol Pathol 1968;9:79-90.
24. Tran-Thi TA, Phillips J, Falk H, Decker K. Toxicity of D-galactosamine for rat hepatocytes in monolayer culture. Exp Mol Pathol 1985;42:89-116.
25. Mihas AA, Cebellos R, Mihas TA, Hirschowitz BI. Modification of the hepatotoxicity of D-galactosamine in the rat by an anti-endotoxin. J Med 1990;21:301-11.
26. Ryan CJ, Aslam M, Courtney JM. Transference of hepatic coma to normal rats from galactosamine treated donors by reverse plasma exchange. Biomater Artif Cells Artif Org 1990;18:477-82.
27. Leist M, Wendel A. Tumor necrosis factor induces programmed cell death in mouse hepatocyte cultures. Care Med 1994;20:S94.
28. Leist M, Gantner F, Jilg S, Wendel A. Activation of the 55 KDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. J Immunol 1995;154:1307-16.
29. Nagaki M, Muto Y, Ohnishi H, et al. Hepatic injury and lethal shock in galactosamine-sensitized mice induced by the superantigen staphylococcal enterotoxin B. Gastroenterology 1994;106:450-8.
30. Tiegs G, Wolter M, Wendel A. Tumor necrosis factor is a terminal mediator in galactosamine/endotoxin-induced hepatitis in mice. Biochem Pharmacol 1989;38:627-31.
31. Everaerdt B, Brouckaert P, Fiers W. Recombinant Il-1 receptor antagonist protects against TNF-induced lethality in mice. J Immunol 1994;152:5041-9.
32. Pavlé P, Yates J, Kynaston HG, Parsons KF, Jenkins SA. Hepatosplanchnic haemodynamics and renal blood flow and function in rats with liver failure. Gut 1998;43:272-9.
33. Grewe M, Gausling R, Gyufko K, Hoffmann R, Decker K. Regulation of the mRNA expression for tumor necrosis factor-alpha in rat liver macrophages. J Hepatol 1994;20:811-8.
34. Tran-Thi TA, Decker K, Baeuerle PA. Differential activation of transcription factors NF-kappa B and AP-1 in rat liver macrophages. Hepatology 1995;22:613-9.
35. 2 inhibits the release of tumor necrosis factor-alpha, rather than interleukin 1 beta, from human macrophages. Immunol Lett 1992;31:85-90.
36. Pruimboom WM, Van Dijk JA, Tak CJ, et al. Interactions between cytokines and eicosanoids: a study using human peritoneal macrophages. Immunol Lett 1994;41:255-60.
37. 2 and cyclic nucleotides. J Immunol 1988;141:2388-93.
38. 4 and PAF. Mediators Inflamm 1992;1:5-8.
39. Santucci L, Fiorucci S, Giansanti M, Brunori PM, Di Matteo FM, Morelli A. Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumour necrosis factor alpha. Gut 1994;35:909-15.
40. Schade UF, Burmeister I, Engel R, Reinke M, Wolter DT. Lipoxygenase inhibitors suppress formation of tumor necrosis factor in vitro and in vivo. Lymphokine Res 1989;8:245-50.
41. Wallach D, Holtmann H, Engelmann H, Nophar Y. Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1. J Immunol 1989;140:2994-9.
42. Mortensen RF, Shapiro J, Lin B, Douches S, Neta R. Interaction of recombinant IL-1 and recombinant tumor necrosis factor in the induction of mouse acute phase proteins. J Immunol 1988;140:2260-6.
43. Bohlinger I, Leist M, Barsig J, Uhlig S, Tiegs G, Wendel A. Interleukin-1 and nitric oxide protect against tumor necrosis factor α-induced liver injury through distinct pathway. Hepatology 1995;22:1829-37.
44. Leon P, Redmond P, Shou J, Daly JM. Interleukin 1 and its relationship to endotoxin tolerance. Arch Surg 1992;127:146-51.